News

At present, Dynavax has global rights to continue the development of DV1179 and other TLR 7/9 inhibitors for all indications. As part of the deal, Dynavax carried out

In consideration for the Technology, the Company paid to Ms. Arnett and Mr. Hargreaves a total of USD $100,000 and issued to Ms. Arnett and Mr. Hargreaves options

Recent data suggest that patients who are PD-L1 positive and have increased tumor-infiltrating lymphocytes (TILs) are more likely to respond to anti-PD-1/PD-L1 mAbs compared to patients who are

The CDP was prepared in collaboration with d3 Medicine and contains detailed plans for all pre-clinical tasks including pharmacology, pharmacokinetics, manufacturing, formulation and toxicology of MetaMx. Arch Biopartners

"We are particularly proud of this filing, as it represents our commitment to YONDELIS and the people it may help," said Peter F. Lebowitz, M.D., Ph.D., Global Oncology

The trial showed bioequivalence between the liquid and lyophilised formulations of caplacizumab. To date, the liquid formulation has been used in clinical trials but the lyophilised form is

As part of the deal, Illumina will provide its research use only Nextera Rapid Capture Enrichment kits and NGS technology to a multi-arm, early-stage National Lung Matrix Trial

The initial daclatasvir NDA submitted by the company to the FDA focused on the drug’s use in combination with asunaprevir, an NS3/4A protease inhibitor. Given the withdrawal of

FTC has also approved creation of a consumer healthcare joint venture (JV) by combining GSK’s Consumer Healthcare business and Novartis’ over-the-counter (OTC) Consumer Healthcare business. Novartis has agreed